AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines.
Imperfect balance sheet with concerning outlook.
Share Price & News
How has AB Science's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AB exceeded the French Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: AB exceeded the French Market which returned -12% over the past year.
Price Volatility Vs. Market
How volatile is AB Science's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWhat Kind Of Shareholders Own AB Science S.A. (EPA:AB)?
2 months ago | Simply Wall StHow Much is AB Science S.A.'s (EPA:AB) CEO Getting Paid?
3 months ago | Simply Wall StAnnouncing: AB Science (EPA:AB) Stock Increased An Energizing 115% In The Last Year
Is AB Science undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether AB Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AB Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of AB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through AB Science regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is AB Science forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if AB's forecast earnings growth is above the savings rate (0.6%).
Earnings vs Market: Insufficient data to determine if AB's earnings are forecast to grow faster than the French market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AB's revenue (5.6% per year) is forecast to grow faster than the French market (4% per year).
High Growth Revenue: AB's revenue (5.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AB's Return on Equity is forecast to be high in 3 years time
How has AB Science performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AB is currently unprofitable.
Growing Profit Margin: AB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AB is unprofitable, and losses have increased over the past 5 years at a rate of -2.8% per year.
Accelerating Growth: Unable to compare AB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7%).
Return on Equity
High ROE: AB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is AB Science's financial position?
Financial Position Analysis
Short Term Liabilities: AB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AB has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AB has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: AB is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.
What is AB Science's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AB's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Alain Moussy, MBA is a Co-Founder of AB Science S.A. and has been its Chief Executive Officer since July 2001. Mr. Moussy has been Scientific Director at AB Science S.A. since January 2004. He serves a ...
CEO Compensation Analysis
Compensation vs Market: Alain's total compensation ($USD529.50K) is about average for companies of similar size in the French market ($USD668.91K).
Compensation vs Earnings: Alain's compensation has increased whilst the company is unprofitable.
|Director||18.83yrs||no data||no data|
|Director||18.83yrs||no data||no data|
|Independent Director||4.75yrs||no data||no data|
|Director||2.42yrs||no data||no data|
|Independent Director||1.92yrs||no data||no data|
|1.92yrs||no data||no data|
Experienced Board: AB's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.2%.
AB Science S.A.'s company bio, employee growth, exchange listings and data sources
- Name: AB Science S.A.
- Ticker: AB
- Exchange: ENXTPA
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €370.890m
- Shares outstanding: 44.58m
- Website: https://www.ab-science.com
Number of Employees
- AB Science S.A.
- 3, Avenue George V
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AB||ENXTPA (Euronext Paris)||Yes||Common Shares||FR||EUR||Apr 2010|
|A8D||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 2010|
|0Q77||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Apr 2010|
|ABSC.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Apr 2010|
|ABP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Apr 2010|
AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/27 22:31|
|End of Day Share Price||2020/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.